DARA BioSciences (DARA) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for US Patent Application No 12/112,213 entitled “Methods for Decreasing or
Merck & Co has outlined its global plans after Merk’s merger with Schering-Plough. The new Merck will be a global health care leader aimed at providing innovative, distinctive
Abraxis Health, a fully-integrated personalised healthcare division of Abraxis BioScience, has dedicated its new manufacturing facility in Phoenix, Arizona. The biopharma manufacturing plant represents a $70m investment by
Peregrine Pharmaceuticals has received US Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies. It also includes Peregrine’s lead clinical compound, bavituximab. PS
Emerson Resources has formed a strategic partnership with Bio Research, to further extend its business development capabilities. The partnership leverages the expertise of industry veteran Robert Westbrook, CEO
FDA has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, Shire’s enzyme replacement therapy in development for the treatment of type 1 Gaucher disease.
Alnylam has advanced the RNAi therapeutic collaboration stage of its alliance with Roche formed in 2007. In this phase of the collaboration, the partners are expected to jointly
PuraMed BioScience has accelerated the construction of its e-commerce website due to the volume of calls coming into the company’s headquarters inquiring when its migraine headache treatment LipiGesic
Arch Chemicals has reported sales of $350.5m for the third quarter of 2009, compared to $367.9m for the same period of 2008. Higher pricing and the benefit from
Sinus Dynamics has discovered a treatment for Nasal Allergies, Sinus Infections and Sinusitis by combining antibiotic and anti-inflammatory medications. The company said that it offers combined antibiotic and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.